| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/13/1993 | US5227467 Containing fluorinated valine residue |
| 07/13/1993 | US5227466 Insulin receptor binding site |
| 07/13/1993 | US5227397 Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels |
| 07/13/1993 | US5227369 Carbohydrate blocking agent which inhibits LHR-mediated binding of leukocytes to myelin |
| 07/13/1993 | US5227368 Endotoxin-induced thrombosis factor which induces procoagulant activity in endothelial cells |
| 07/13/1993 | US5227302 DNA encoding platelet derived endothelial cell growth factor (PD-ECGF) |
| 07/13/1993 | US5227294 Method of producing surfactin with the use of mutant of bacillus subtilis |
| 07/13/1993 | US5227161 Method to clean and disinfect pathogens on the epidermis by applying a composition containing peroxidase, iodide compound and surfactant |
| 07/13/1993 | US5227160 Contraceptives, treatment of infertility |
| 07/13/1993 | US5227158 Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| 07/13/1993 | US5227154 Phosphopeptides for the treatment of dental calculus |
| 07/13/1993 | US5226877 Method and apparatus for preparing fibrinogen adhesive from whole blood |
| 07/13/1993 | CA1320310C 4-aminopyridine derivatives and their acid addition salts |
| 07/13/1993 | CA1320160C Monoclonal antibodies against ifn-omega, processes for preparing them and their use in the purification and detection of ifn-omega |
| 07/13/1993 | CA1320129C Synergistic behavior of csf-1 and g-csf |
| 07/08/1993 | WO1993013421A1 Immunochemical detection of in vivo advanced glycosylation endproducts |
| 07/08/1993 | WO1993013417A1 Receptor/oncogene growth factor system in breast cancer |
| 07/08/1993 | WO1993013222A1 Dna structure-specific recognition protein and uses therefor |
| 07/08/1993 | WO1993013218A1 Endothelin-antagonizing peptide |
| 07/08/1993 | WO1993013211A1 Expression and purification of recombinant soluble tissue factor |
| 07/08/1993 | WO1993013210A1 Icams immunoglobulin constant region soluble fusion proteins |
| 07/08/1993 | WO1993013209A1 Expression signal-peptide-free staphylokinases |
| 07/08/1993 | WO1993013208A1 Methods for producing thrombin |
| 07/08/1993 | WO1993013207A2 Novel human transglutaminases |
| 07/08/1993 | WO1993013206A1 Stem cell inhibiting proteins |
| 07/08/1993 | WO1993013204A2 Agent for stimulating animal cell division |
| 07/08/1993 | WO1993013202A1 Immunogenic detoxified mutants of cholera toxin and of the toxin lt, their preparation and their use for the preparation of vaccines |
| 07/08/1993 | WO1993013201A1 Lipopolysaccharide binding opsonin inhibitor and methods of use thereof |
| 07/08/1993 | WO1993013199A1 A gene and the enzyme encoded by this gene |
| 07/08/1993 | WO1993013133A1 HUMAN TYPE ANTIBODY REACTIVE WITH GPIIb/IIIa |
| 07/08/1993 | WO1993013132A1 Novel megakaryocyte amplifier |
| 07/08/1993 | WO1993013128A1 Methods of producing analgesia and enhancing opiate analgesia |
| 07/08/1993 | WO1993013126A1 Peptide compounds having therapeutic activity |
| 07/08/1993 | WO1993013121A1 Gapped 2' modified oligonucleotides |
| 07/08/1993 | WO1993013119A1 Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof |
| 07/08/1993 | WO1993013089A1 Macrocyclic polyether carboxylic acids |
| 07/08/1993 | WO1993013065A1 Proline derivative |
| 07/08/1993 | WO1993012819A1 Protein- and peptide-metal ion pharmaceutical applications |
| 07/08/1993 | WO1993012816A1 Monoclonal antibodies against type i phospholipase a2, used as a therapeutic agent to reduce inflammation |
| 07/08/1993 | WO1993012814A2 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| 07/08/1993 | WO1993012813A1 Methods and compositions for reducing blood loss |
| 07/08/1993 | WO1993012812A1 A stabilized pharmaceutical formulation comprising growth hormone and histidine |
| 07/08/1993 | WO1993012811A1 A stabilized pharmaceutical formulation comprising growth hormone and asparagine |
| 07/08/1993 | WO1993012810A1 Pharmaceutical pentapeptide compositions and methods of use thereof |
| 07/08/1993 | WO1993012809A1 Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
| 07/08/1993 | WO1993012808A1 A method for treating kaposi's sarcoma and blocking or inhibiting vascular permeability |
| 07/08/1993 | WO1993012807A1 Bone reinforcing factor, and food and drink containing said factor |
| 07/08/1993 | WO1993012803A1 Growth-simulating material, process for preparing the same and therapeutical composition |
| 07/08/1993 | WO1993012796A1 Use of renin inhibitors for the treatment of glaucoma |
| 07/08/1993 | WO1993012791A1 Central cholecystokinin antagonists having pharmaceutical activity |
| 07/08/1993 | WO1993012781A2 Creatine analogs having antiviral activity |
| 07/08/1993 | WO1993012777A1 Use of polyamines as ionic-channel regulating agents |
| 07/08/1993 | WO1993012756A2 Transfection of lung via aerosolized transgene delivery |
| 07/08/1993 | WO1993012736A1 Mineralized collagen |
| 07/08/1993 | WO1993012139A1 A novel molecule which inhibits neuropeptide tyrosine biological function |
| 07/08/1993 | WO1992017077A3 Fat substitute compositions having reduced laxative effects |
| 07/08/1993 | DE4200049A1 New monoclonal antibodies specific for tumour necrosis factor binding protein |
| 07/08/1993 | DE4143279A1 New DNA sequence encoding staphylokinase - with corresp. proteins used as plasminogen activators in treatment of thrombosis |
| 07/08/1993 | CA2127275A1 Pharmaceutical pentapeptide compositions and methods of use thereof |
| 07/08/1993 | CA2126686A1 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| 07/08/1993 | CA2126236A1 Peptide compounds having therapeutic activity |
| 07/08/1993 | CA2126212A1 A novel molecule which inhibits neuropeptide tyrosine biological function |
| 07/08/1993 | CA2126211A1 Use of renin inhibitors for the treatment of glaucoma |
| 07/08/1993 | CA2126209A1 Immunochemical detection of in vivo advanced glycosylation endproducts |
| 07/08/1993 | CA2126108A1 A method for treating kaposi's sarcoma and blocking or inhibiting vascular permeability |
| 07/08/1993 | CA2125856A1 A stabilized pharmaceutical formulation comprising growth hormone and asparagine |
| 07/08/1993 | CA2125563A1 Creatine analogs having antiviral activity |
| 07/08/1993 | CA2104952A1 Endothelin-antagonizing peptide |
| 07/07/1993 | EP0550400A2 Modular assembly of antibody genes, antibodies prepared thereby and use |
| 07/07/1993 | EP0550376A1 Procedure for producing a polypeptide-type product having an inhibiting effect on hyperproduction of the tumor necrosis factor |
| 07/07/1993 | EP0550296A2 Vascular endothelial cells growth factor |
| 07/07/1993 | EP0550035A2 Composition of stabilized fibroblast growth factor |
| 07/07/1993 | EP0549915A1 New synthetic isohirudines with enhanced stability |
| 07/07/1993 | EP0549742A1 USE OF CANPs-INHIBITORS IN PHARMACEUTICAL PREPARATIONS |
| 07/07/1993 | EP0549727A1 Carboxylic acid esters of rapamycin |
| 07/07/1993 | EP0549723A1 Packaging cells |
| 07/07/1993 | EP0549711A1 Natural killer stimulatory factor |
| 07/07/1993 | EP0549702A1 Uses of recombinant colony stimulating factor-1 |
| 07/07/1993 | EP0549691A1 Gene therapy for cystic fibrosis |
| 07/07/1993 | EP0549662A1 Plasmodium liver stage antigens |
| 07/07/1993 | EP0549615A1 Sugar modified oligonucleotides that detect and modulate gene expression |
| 07/07/1993 | EP0542934A4 Method of treating benign and malignant proliferative skin disease |
| 07/07/1993 | EP0380554B1 Vasoactive peptides |
| 07/07/1993 | EP0287633B1 Combinations of tumor necrosis factors and anti-inflammatory agents for treating malignant and non-malignant diseases |
| 07/07/1993 | CN1073980A Collagen-like polypertides |
| 07/07/1993 | CN1073979A A87689 compounds |
| 07/07/1993 | CN1073978A Novel synthetic isohirudins with improved stability |
| 07/07/1993 | CN1073976A Tissue-selective insulin anaiogs |
| 07/06/1993 | US5225541 Composition containing CEA/NCA-specific monoclonal antibody XMMBR-B14 conjugated to a detectable moiety and a kit containing the antibody |
| 07/06/1993 | US5225540 Hybridomas and Fab fragments |
| 07/06/1993 | US5225538 Diagnostic, theraputic |
| 07/06/1993 | US5225535 Lymphokine SAF and method of making |
| 07/06/1993 | US5225532 Symmetrical bipeptides containing a polyalkylene glycol residue, method of preparation and use in the assay of proteases |
| 07/06/1993 | US5225531 Hexapeptide Lys Gly Ala Gly Asp Val |
| 07/06/1993 | US5225401 Endopeptidase inhibitors for congestive heart failure |
| 07/06/1993 | US5225400 Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them |
| 07/06/1993 | US5225399 Antimicrobial amphiphilic peptides |
| 07/06/1993 | US5225347 Therapeutic ribozyme compositions and expression vectors |
| 07/06/1993 | US5225337 Ribozyme compositions and methods for use |
| 07/06/1993 | US5225323 Human high-affinity neurotransmitter uptake system |